Case study: establishing a versatile and intensified lentiviral vector production platform with TFDF

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Case study: establishing a versatile and intensified lentiviral vector production platform with TFDF

To overcome process limitations in lentiviral vector (LVV) production, low vector yields and high CoGs must be addressed by implementing optimized manufacturing strategies to improve efficiency, scalability, and accessibility.

In this webinar, we will present a case study detailing the robust development undertaken at a small-scale to develop a high-producing transient-transfection LVV platform in suspension HEK293, showing how ReciBioPharm’s batch LLV production process achieved yields of greater than 2.0x10⁸ TU/mL.

Find out how to accelerate process development and leverage an optimized LVV production process to achieve higher yields and more efficient scale-up
Learn how TFDF perfusion can enhance process intensification by significantly boosting viable cell density while maintaining quality and removing potential transfection inhibitors
See case study data demonstrating how adopting continuous TFDF perfusion harvesting can result in industry-leading LVV titers, improving process yields by > 4X

Chris Brown

Senior Scientist, Viral Vector Process Development at ReciBioPharm

Chris Brown is a Process Development Senior Scientist at ReciBioPharm, the biologics division of the global CDMO Recipharm. Chris holds Bachelors (BSc) and Masters (MS) degrees in Chemical Engineering from Northeastern University. He has greater than 8 years of experience across both process development and CMC, with six of those years dedicated specifically to the advancement of rAAV and LVV manufacturing. Chris has been with ReciBioPharm for two years, where he has focused on developing robust, scalable viral vector manufacturing processes and tailoring these processes to meet client needs.

in 15

Days